News releases from Optinose
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Patients Who Remain Symptomatic After Treatment with Standard Nasal Steroid Sprays
September 29, 2020
Improvement was observed across a broad range of measures including multiple symptoms and both general and disease-specific quality of life
Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps
September 18, 2017
Optinose, an ENT / Allergy specialty pharmaceutical company, announced today that the U.S. Food & Drug Administration (FDA) approved the Company’s New Drug Application (NDA) for XHANCE (previously...
OptiNose, a commercial-stage ENT / Allergy specialty pharmaceutical company, today announced that it has closed a $37 million Series D financing led by Fidelity Management and Research Company with...
Michael F. Marino Joins OptiNose as Chief Legal Officer
February 09, 2017
OptiNose™ today announced the appointment of Michael F. Marino as Chief Legal Officer. Mr. Marino is a seasoned executive and legal advisor with more than 15 years of experience advising public and...
OptiNose Announces FDA Acceptance for Filing of the New Drug Application for OPN-375
January 31, 2017
OptiNose™ today announced the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for the investigational new product OPN-375. OptiNose is seeking...
OptiNose Appoints Keith Goldan as Chief Financial Officer
January 26, 2017
OptiNose today announced the appointment of Keith A. Goldan as Chief Financial Officer (CFO). Mr. Goldan brings to the company more than 25 years of executive finance and operational leadership in...
CORRECTING and REPLACING OptiNose to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 21, 2016
New Research Highlights the Burden of Illness Suffered by Chronic Rhinosinusitis Patients
September 19, 2016
According to new research presented today at the American Rhinologic Society Annual Meeting, an estimated 28 million Americans are currently suffering from the symptoms of Chronic Rhinosinusitis (CRS)...
CORRECTING and REPLACING OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis (CRS)
September 16, 2016
In the original release, there were two instances (second bullet under NAVIGATE II and first bullet under EXHANCE-12) where dosage amounts of EDS-FLU read 371 µg twice daily; these should have read 372...
OptiNose Announces FDA Approval for ONZETRA™ Xsail™ (sumatriptan nasal powder), a New Treatment for Acute Migraine Using Bi-Directional™ Breath Powered® Technology
January 28, 2016
OptiNose, a privately-held specialty biopharmaceutical company, today announced that its licensing partner, Avanir Pharmaceuticals, Inc. has reported that the U.S. Food & Drug Administration (FDA)...
OptiNose to Present at the 34th Annual J.P. Morgan Healthcare Conference
December 17, 2015
OptiNose today announced that the company will present at the 34th annual J.P. Morgan Healthcare Conference. CEO Peter Miller will discuss the Company's recent milestones, pipeline and strategy for...
OptiNose Closes New Round of Financing
October 06, 2015
OptiNose, a specialty biopharmaceutical company, announced today that it has closed a new round of financing providing up to $30M in additional capital. Since completing its previous financing round in...
OptiNoseTM Announces Positive Results of Second Phase III Pivotal Trial for OPN-375
September 24, 2015
OptiNose today announced positive results from a second phase III pivotal trial, NAVIGATE I. This follows and helps both to confirm and support the positive results from a first pivotal trial, NAVIGATE...
OptiNose to Present at the 35th Annual Cowen Healthcare Conference
February 23, 2015
OptiNose to Present at the 33rd Annual J.P. Morgan Healthcare Conference
December 18, 2014
OptiNose Announces Publication of Pivotal Phase III Results for Investigational Migraine Treatment Developed by OptiNose Using Bi-Directional™ Breath Powered™ Technology
October 31, 2014
OptiNose Completes Series C-1 Financing
August 04, 2014
Current Investors and Management Increase Support for OptiNose and the Company's Breakthrough New Product, OPN-375
OptiNose Expands Senior Management Team with Three Key Appointments in Core Business Areas of Operations, Regulatory Affairs and Commercialization
June 12, 2014
OptiNose Announces Positive Results of COMPASS: A Head-to-Head Comparison of a New Migraine Treatment Using Bi-Directional™ Breath Powered™ Technology (AVP-825) versus Oral Sumatriptan
June 10, 2014
AVP-825, Using OptiNose's Patented Bi-Directional™ Breath Powered™ Technology for Intranasal Delivery of Low-dose Sumatriptan, Demonstrates Greater Reduction in Migraine Pain Compared to the Highest...
OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
March 27, 2014
OptiNose Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device
February 09, 2012